NMT Medical, Inc Clinical Trial Data Presented At The TCT Symposium

WASHINGTON, Oct. 20 /PRNewswire-FirstCall/ -- NMT Medical, Inc. announced today that the preliminary clinical results from its BEST (BioSTAR(TM) Evaluation STudy) clinical study and additional data from its MIST (Migraine Intervention with STARFlex(R) Technology) clinical trial were presented at the 2005 Transcatheter Cardiovascular Therapeutic symposium (TCT). TCT is the largest interventional cardiologist meeting in the world and is held annually in Washington, D.C.

The multi-center BEST study is evaluating NMT's new bioabsorbable collagen matrix PFO (patent foramen ovale) closure technology. The study is being led by Michael Mullen, MD, Interventional Cardiologist at Royal Brompton Hospital, London, and Chief Investigator for BEST.

In his presentation on BEST, Dr. Mullen said, "We view BioSTAR(TM) as a very promising implant technology. Improved treatments for patients with structural heart defects, such as PFOs, are highly sought after in the medical community. Based on our clinical research, it appears that BioSTAR(TM), which is delivered by transcatheter technique, offers a more rapid and complete sealing of the PFO defect than current methods."

Dr. Mullen reported on the first 30 BioSTAR(TM) patients that have reached 30 days of post-procedure follow up. Acutely, no device-related thrombus, which occasionally occurs in all intra-cardiac devices, was observed. NMT's BioSTAR(TM) has a drug-eluting capability and the BioSTAR(TM) implants in BEST provided an elutable heparin substrate, which is designed to enhance the healing process and minimize thrombus formation.

Closure rate data from BEST also was reported on the first 15 BioSTAR(TM) patients. At 30 days, a small residual leak was seen in one of those 15 patients with complete closure in the rest. No major adverse events were reported.

In a "Featured Presentation," updated data from NMT's MIST study was presented by Peter Wilmshurst, MD, Consultant Cardiologist at Royal Shrewsbury Hospital, Shrewsbury, England and co-primary investigator of the study.

Dr. Wilmshurst discussed the 432 migraine patients prospectively studied in MIST. Of that total, 260, or 60%, were found to have a right to left shunt, or flow of venous blood into the arterial circulation. Dr. Wilmshurst said, "What's remarkable in this data is that more than 40% of the patients had a large shunt, which is six times greater than what is observed in the general population." Full data on MIST is expected to be reported in late March/early April 2006.

John E. Ahern, NMT's President and Chief Executive Officer, said, "We are pleased with the initial BioSTAR(TM) patient outcomes. We believe that if approved, BioSTAR(TM) will give us a strong competitive advantage over conventional PFO closure implants. The MIST data continues to support the PFO/migraine connection, and we are hopeful to report positive treatment outcomes in the near future."

NMT recently received approvals to initiate enrollment in its MIST II multi-center IDE study in the United States and MIST III in the United Kingdom.

Ahern concluded, "NMT Medical is committed to building its clinical research and technology leadership in the PFO-closure field. BioSTAR(TM) and the BEST study, in combination with our MIST trials, are an important part of that leadership strategy. We are very positive about the progress we are making and the milestones the Company achieved in 2005."

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter- based procedures. NMT Medical is investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and transient ischemic attacks (TIAs). A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. More than 18,000 PFOs have been closed globally with NMT's implant technology.

The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and 500,000 Americans experience a TIA.

The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements -- including statements regarding the outcomes of the Company's BEST, MIST, MIST II and MIST III clinical trials, the Company's market opportunities, including migraines, and regulatory approvals for the Company's products -- involve known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may cause such a difference include, but are not limited to, the timing and outcome of the Company's BEST, MIST, MIST II and MIST III clinical trials, the Company's ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading "Certain Factors That May Affect Future Results" included in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 and subsequent filings with the U.S. Securities and Exchange Commission.

Contact: John E. Ahern President and Chief Executive Officer NMT Medical, Inc. (617) 737-0930 jea@nmtmedical.com

NMT Medical, Inc.

CONTACT: John E. Ahern, President and Chief Executive Officer of NMTMedical, Inc., +1-617-737-0930, jea@nmtmedical.com

Back to news